An Extension Study to Assess the Long-term Safety and Efficacy of Hunterase (Idursulfase Beta)
Status:
COMPLETED
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the long-term safety and efficacy of Hunterase for approximately 1 year in subjects who completed the end of study (EOS) visit (Visit 54) tests in the Phase 3 Hunterase study and patients who received Hunterase for more than 6 months
Phase:
PHASE3
Details
Lead Sponsor:
GC Biopharma Corp
Collaborator:
Samsung Medical Center, Sungkyunkwan University School of Medicine